Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 135 member B (FAM135B)
- Target
- FAM135B
- Molecular classification
- Other (uncharacterized protein family; not a receptor, enzyme, ion channel, transporter, or transcription factor), Contains domains of unknown function (DUF676, DUF3657), one of which may be a putative serine esterase
01
Overview
Family with sequence similarity 135 member B (FAM135B) encodes a large protein of unknown definitive function, with domains DUF676 (putative serine esterase) and DUF3657, expressed in various healthy tissues including brain and pancreas, and more strongly in certain tumors. Its high expression in ESCC tumors correlates with advanced stage, lymph node metastasis, and radioresistance, acting as a context-dependent promoter of cell proliferation and survival via the PI3K/Akt/mTOR pathway. In contrast, reduced FAM135B is implicated in neurodegenerative phenotypes. Genetic variation in FAM135B may also affect immune response and susceptibility to infectious disease, such as tuberculosis. Although FAM135B has no direct interacting drugs, its expression levels serve as a potential biomarker for cancer progression and treatment response
- Other names
- FAM135BC8orfK32C8ORFK32Family with sequence similarity 135 member Bprotein FAM135B
02
Mechanism of action
Drugs impacting pathways in which FAM135B is involved (e.g., PI3K/Akt/mTOR in ESCC) may mediate antiproliferative or radiosensitizing effects, but no agent specifically targeting FAM135B has been reported
03
Biological functions
Cell proliferation (promotes ESCC cell cycle progression and colony formation)Survival and radioresistance (confers resistance to irradiation in tumor cells)Neuroprotection (supports motor neuron health, with loss leading to neurodegeneration)Modulation of immune response and infection susceptibility (implicated in extrapulmonary tuberculosis through genetic variation)
04
Disease associations
Cancer (oncogenic driver in ESCC; expression linked to advanced stage and poor radioresponse)Neurodegenerative disease (decreased expression in spinal and bulbar muscular atrophy motor neurons)Infection (polymorphisms associated with extrapulmonary tuberculosis)
05
Safety considerations
No direct safety concerns or therapeutic challenges have been published specific to FAM135B targeting or modulation, likely because it is not yet a direct drug target
06
Interacting drugs
No specific drugs are documented to act directly on FAM135B as a target as of current literature
07
Biomarkers
FAM135B gene/protein expression is a candidate biomarker for diagnosis and prognosis in ESCC and possibly as a marker for radioresistance in this cancer
Beyond the preview
Go deeper on Family with sequence similarity 135 member B (FAM135B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Family with sequence similarity 135 member B (FAM135B).